ATC Group: H01CC03 Elagolix

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H01CC03 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H01 Pituitary and hypothalamic hormones and analogues
3 H01C Hypothalamic hormones
4 H01CC Anti-gonadotropin-releasing hormones
5 H01CC03

Active ingredients in H01CC03

Active Ingredient Description
Elagolix

Elagolix is a GnRH receptor antagonist that inhibits endogenous GnRH signaling by binding competitively to GnRH receptors in the pituitary gland. Administration of elagolix results in dose-dependent suppression of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to decreased blood concentrations of the ovarian sex hormones, estradiol and progesterone.

Related product monographs

Title Information Source Document Type  
ORILISSA Film-coated tablet FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Canada (CA)

Israel (IL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.